Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: The US Food and Drug Administration has recently granted accelerated approval of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib as treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious germline or somatic BRCA1 or BRCA2 (BRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Labadie, Brian W, Morris, David S, Bryce, Alan H, Given, Robert, Zhang, Jingsong, Abida, Wassim, Chowdhury, Simon, Patnaik, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860352/
https://www.ncbi.nlm.nih.gov/pubmed/35210863
http://dx.doi.org/10.2147/CMAR.S335962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860352/
https://www.ncbi.nlm.nih.gov/pubmed/35210863
http://dx.doi.org/10.2147/CMAR.S335962

Ejemplares similares